Leishmaniasis News and Research

RSS

Leishmaniasis is a parasitic disease transmitted by the bite of infected sand flies. It is found in nearly 88 countries, from rain forests in Central and South America to deserts in the Middle East and west Asia. Some cases of the disease have also appeared in Mexico and Texas.

Leishmaniasis takes several different forms, including the most common cutaneous leishmaniasis, which causes skin sores, and the more severe visceral leishmaniasis, which affects internal organs such as the spleen, liver, and bone marrow. The World Health Organization (WHO) estimates that there are 1.5 million new cases of cutaneous leishmaniasis and 500,000 new cases of visceral leishmaniasis in the world each year.

Fexinidazole enters Phase II/III clinical study to treat sleeping sickness

A new oral-only treatment for sleeping sickness has entered Phase II/III clinical study in patients with late-stage sleeping sickness in the Democratic Republic of the Congo (DRC) and soon in Central African Republic (CAR).

6 Dec 2012

Malaria Box helps identify three chemical series that target treatment of NTDs

The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi's screening of MMV's open access Malaria Box.

14 Nov 2012

TB Alliance and FIND partner to promote development of TB drugs and diagnostics

A new partnership announced today will increase efforts to coordinate the development of complementary novel tools to fight TB, including drug-resistant TB, and identify emerging drug resistance trends around the globe.

19 Oct 2012

Financial Times features special report on NTDs

The Financial Times has published a special report on neglected tropical diseases (NTDs) featuring 10 articles examining issues including prevention, research, and treatment.

12 Oct 2012

IPS examines debate over impact of climate change on health

"More intense rainfall, rising temperatures and climate-driven migration of human and animal populations due to repeated drought all affect the spread of tropical diseases," Inter Press Service writes in an article examining the impact of climate change on health, a topic that "generated debate among the experts attending the 18th International Congress on Tropical Medicine and Malaria, held Sept. 23-27 in Rio de Janeiro."

2 Oct 2012

Kenyan government releases new guidelines for treatment, prevention of visceral leishmaniasis

"The Kenyan government has launched guidelines for the treatment and prevention of visceral leishmaniasis, also known as kala azar or black fever, in a move government officials say is meant to contain the parasitic disease, which is endemic in the northern region of the country," IRIN reports.

29 Sep 2012

FIOCRUZ, DNDi and Brazil collaborate on R&D for neglected diseases

At the opening ceremony of the XVIII International Congress for Tropical Medicines and Malaria (ICTMM) and the XLVIII Congress of the Brazilian Society of Tropical Medicine in Rio de Janeiro, the Ministry of Health of Brazil signed a Cooperation and Technical Assistance Agreement with the Oswaldo Cruz Foundation (FIOCRUZ) and the Drugs for Neglected Diseases initiative (DNDi) Latin America, uniting the three actors into a strategic partnership to collaborate on research and development (R&D) for new therapies and diagnostics for neglected diseases.

25 Sep 2012

'Greater commitment' needed to fight NTDs

In a guest post on USAID's "IMPACT Blog," Rachel Cohen, regional executive director of DNDi North America, writes, "The United States government and its country partners should be commended for the tremendous achievements in the fight against neglected tropical diseases (NTDs) as part of the U.S. Agency for International Development (USAID) NTD Program" and the National Institutes of Health.

20 Sep 2012

Recent release: AIDS 2012 panel discussion highlighted link between HIV/AIDS, NTDs

"On Wednesday, July 25, the Global Network for Neglected Tropical Diseases [NTDs] co-chaired a panel at the XIX International AIDS Conference (AIDS 2012), addressing the link between NTDs and HIV/AIDS," the network's "End the Neglect" blog reports.

28 Jul 2012

Cipla, DNDi to develop ARV combination therapy for children with HIV/AIDS

On the eve of the XIX International AIDS Conference in Washington, DC, the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, announces a new collaboration with Indian drug manufacturer Cipla to develop and produce an improved first-line antiretroviral (ARV) combination therapy specifically adapted to meet the treatment needs of infants and toddlers living with HIV/AIDS.

21 Jul 2012

Scientists develop simple assay to diagnose 'superparasites'

Belgian scientists of the Institute of Tropical Medicine (ITM) in Antwerp, Belgium made a breakthrough in bridging high tech molecular biology research on microbial pathogens and the needs of the poorest of the poor. After sequencing the complete genome of Leishmania donovani (a parasite causing one of the most important tropical diseases after malaria) in hundreds of clinical isolates, they identified a series of mutations specific of 'superparasites' and developed a simple assay that should allow tracking them anywhere.

20 Jul 2012

Microbiologists reveal how T. brucei’s key proteins organize to replicate its mtDNA

A group of diseases that kill millions of people each year can't be touched by antibiotics, and some treatment is so harsh the patient can't survive it. They're caused by parasites, and for decades researchers have searched for a "magic bullet" to kill them without harming the patient. Now, a team of microbiologists at the University of Massachusetts Amherst has made an advance that could one day lead to a new weapon for fighting parasitic diseases such as African sleeping sickness, chagas disease and leishmaniasis.

11 Jul 2012

DNDi, Astellas partner on new drug discovery research for treatment of NTDs

Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.

12 Jun 2012

Leishmaniasis vaccine trial begins in U.S., India

"A vaccine against one of the most neglected yet fatal tropical diseases is being tested for the first time in a clinical trial in India and the U.S.," IRIN reports. Visceral leishmaniasis (VL), "also called kala-azar or black fever, infects an estimated half million persons or more annually," and "it is found most commonly in India, Nepal, Bangladesh, Brazil and Sudan," the news service notes.

10 May 2012

Honduras becomes first LAC country to launch national plan to combat NTDs

"A major milestone was achieved on April 12, when Honduras became the first country in the Latin America and the Caribbean (LAC) region to officially launch an integrated national plan to combat neglected tropical diseases (NTDs)," the the Global Network for Neglected Tropical Diseases' "End the Neglect" blog reports.

20 Apr 2012

DNDi, AstraZeneca enter collaboration on drug-compound screening for NTDs

AstraZeneca and the Drugs for Neglected Diseases initiative (DNDi) today announce an agreement to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness, three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.

12 Apr 2012

DNDi commences Oxaborole SCYX-7158 Phase I clinical trial for sleeping sickness

The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.

12 Mar 2012

Researchers begin clinical trial of first visceral leishmaniasis vaccine

"Researchers say they've developed the first vaccine for visceral leishmaniasis (VL) -- a disease that affects 500,000 people each year and has been called the 'parasitic version of HIV,'" although the diseases are unrelated, U.S. News reports.

24 Feb 2012

IDRI launches LEISH-F3 + GLA-SE Phase 1 trial for kala-azar

The first clinical trial of a new vaccine for visceral leishmaniasis (VL) has been launched by the Infectious Disease Research Institute (IDRI), a Seattle-based nonprofit that develops products to prevent, detect, and treat diseases of poverty. The Phase 1 trial is taking place in Washington State, with a companion Phase 1 trial planned in India, an epicenter of the disease.

23 Feb 2012

Grand Challenges Canada announces 15 grants to support rising stars in global health

Grand Challenges Canada today announced 15 grants valued in total at more than $1.5 million awarded to some of Canada's most creative innovators from across the country in support of their work to improve global health conditions.

10 Feb 2012